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ABSTRACT
Objective: Assess within-subject agreement and compare discriminative
abilities between the SF-6D and the Health Utilities Index Mark 3 (HUI3)
in patients with chronic kidney disease (CKD).
Methods: The HUI3 and Short Form-36 were self-completed by 185 CKD
patients enrolled in a prospective study of incident patients with stage 4
and 5 CKD.
Results: The mean preference-based score for the SF-6D was 0.67  0.13
compared to 0.58  0.26 for the HUI3 (P < 0.01). There was a strong
association between SF-6D and HUI3 scores (Pearson correlation coefﬁ-
cient 0.55, 95% CI 0.43–0.65) and moderate agreement with an intraclass
correlation coefﬁcient of 0.44. The HUI3 was better able to capture more
severe burden of illness with fewer ﬂoor effects. The SF-6D was better at
capturing differences among patients at the top range of the scale with
fewer ceiling effects. Both the HUI3 and SF-6D were able to discriminate
between patient groups differing in disease severity deﬁned as predialysis
versus dialysis dependent and depressive symptoms using a Beck Depres-
sion Inventory II score of 14 as the cutoff. The HUI3 was better able to
discriminate greater depressive symptoms.
Conclusion: The SF-6D and the HUI3 generate different preference-based
scores for patients with CKD and any comparison between their scores
should be made with caution. The HUI3 appears more suitable for mea-
suring the health of populations with greater disability such as patients
with CKD. It remains to be determined whether these differences will
remain when one compares within-instrument differences in preference
scores over time.
Keywords: chronic kidney disease, cost-effectiveness, discriminant ability,
HUI3, SF-6D.
Introduction
The ever-increasing demands on health-care systems have stimu-
lated much interest in the cost-effectiveness of health-care inter-
ventions. An important technique for assessing cost-effectiveness
has been cost-utility analysis, which incorporates preferences for
different health states and provides estimates of quality adjusted
survival, expressed as quality-adjusted life-years (QALYs).
Establishing the net effect of an intervention on health-related
quality of life (HRQL) in a single summary score is essential for
cost-effectiveness and cost-utility analyses. Nevertheless, this is
difﬁcult to do with the standard HRQL measures used in studies
of patients with chronic kidney disease (CKD), such as the Short
Form-36 (SF-36) [1] or the Kidney Disease Quality of Life
(KDQOL) questionnaire [2]. The SF-36 and the KDQOL were
not developed to generate a single summary score. Furthermore,
to estimate the QALYs gained by those who receive an interven-
tion, the scoring system needs to be able to integrate mortality
and morbidity. Although the scores derived from the KDQOL
and SF-36 reﬂect morbidity, the scores do not reﬂect mortality.
The health state values used to derive QALYs can be obtained
from multiattribute preference-based HRQL instruments such as
the Health Utilities Index Mark 3 (HUI3) and the SF-6D [3–5].
These systems employ multidomain health-status questionnaires
completed by patients to obtain information on self-assessed
health status. Preference-based scores for those health states are
then calculated using published scoring functions for the two
systems. The published scoring functions are based on preferences
obtained from random samples of the general population, the
United Kingdom for SF-6D [5] and Canada for HUI3 [4]. The
preference-based score for each state is then used to calculate
QALYs by multiplying the score for that health state by the time
that the patient spends in that particular health state. These
multiattribute preference-based instruments are signiﬁcantly less
resource and time-consuming than direct utility or preference
elicitation approaches, such as the standard gamble and time-
trade-off which directly measure the value that patients attach to
their health states [6]. Direct utility assessments are typically
performed by interview and are time-consuming and typically not
feasible in large-scale studies.
There are very limited data with respect to head to head
comparisons of the SF-6D and the HUI3 and we are unaware of
such data in CKD. The purpose of the study was to assess the
within-subject agreement and compare discriminative abilities
between the SF-6D and the HUI3 in patients with CKD.
Methods
Measurement Tools
SF-6D. The SF-6D is a preference-based scoring system derived
from 11 items from six dimensions (“6D”) of the SF-36 covering
physical functioning, role limitations, social functioning, pain,
mental health, and vitality. Each dimension uses four to six levels
where level one represents full functional capacity on a dimen-
sion and levels four to six represent the lowest level of function-
ing on an attribute. The comprehensive health state of an
individual at a point in time is deﬁned as a vector composed of
one level for each dimension. Health-state valuations were
derived for 249 of the possible 18,000 health states using the
conceptual and empirical logic of multiattribute utility theory
(MAUT) [7] from a general population sample in the United
Kingdom using the standard gamble technique. Preference-based
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scores for living states range from 0.296 to 1.0 with 0.296
representing the worst possible SF-6D health state and 1.0 rep-
resenting perfect health; the score for dead is 0.0 [5]. A score
difference of 0.03 on the SF-6D is generally accepted to be
clinically important [8], although a recent article showed the
important clinical difference for the SF-6D to be on average
0.041 across 11 chronic conditions [9]. The SF-6D uses a 4-week
recall period.
HUI. This is a family of generic, multiattribute, preference-
based HRQL instruments [3,10]. The most recent version, the
HUI3, uses ﬁve or six levels for each of eight attributes (vision,
hearing, speech, ambulation, dexterity, cognition, emotion, and
pain) [3,4]. As with the SF-6D, level one represents full func-
tional capacity on an attribute and level ﬁve or six represents the
lowest level of functioning on an attribute. The preference-based
score is computed using MAUT based on preferences of a general
population sample in Canada using a visual analog scale (VAS)
and the standard gamble technique via a transformation of the
VAS. Potential scores range from -0.36 to 1.0 with -0.36 repre-
senting the worst possible HUI3 health state, 0.0 representing
dead, and 1.0 representing perfect health. The standard 15-item
self-completed questionnaire covering both the HUI2 and HUI3
classiﬁcation systems using a 4-week recall period was employed.
A difference of 0.03 on the overall score is considered to be
clinically important [11]. Nevertheless, differences as small as
0.01 in HUI scores have been considered to be important [11].
US and Canadian population norms are available for comparison
[12–14].
Beck Depression Inventory II (BDI-II). This is a 21-item, self-
report scale measuring characteristic attitudes and symptoms of
depression with total scores ranging from 0 to 63 [15]. The scale
has been used extensively in patients with CKD [16–20]. A recent
study showed that the BDI-II cutoff score with the best diagnostic
accuracy for depression in CKD when compared to the Struc-
tured Clinical Interview for Depression was 14 with a sensitivity
of 62% and speciﬁcity of 81% [19].
Charlson Comorbidity Index (CCI) [21]. The CCI was used to
quantify comorbidity. It is commonly used in research with CKD
patients and has been validated speciﬁcally for studies on health
status [22]. The CCI is based on weights for each comorbidity
and age class. The weights express the associated risk of mortal-
ity and are summed to obtain a ﬁnal score [23]. Comorbidity was
deﬁned in terms of presence or absence of disease at the onset of
the study for all predialysis CKD patients and in terms of pres-
ence or absence of disease at the onset of chronic dialysis treat-
ment for all dialysis patients. A CCI score 8 identiﬁes dialysis
patients who have approximately a 50% 1-year mortality rate
[23].
Patients and Procedures
The main study is a prospective study designed to determine the
psychosocial adjustment to illness, depression, HRQL, and eco-
nomic outcomes in incident adult chronic dialysis patients and
patients with stages 4 and 5 CKD who are clinically anticipated
to require dialysis within the next 12 months. Study participants
were recruited from eight hemodialysis units and a large
university-based renal insufﬁciency clinic in northern Alberta,
Canada between January 2005 and June 2006. The inclusion
criteria were 1) stage 4 or 5 CKD with an expected time to
dialysis of less than 12 months (based on the clinical judgment of
the attending nephrologist); 2) patients who had started chronic
hemodialysis within the past 3 months; 3) cognitively able to
complete the questionnaires and give informed consent; and 4)
able to converse and complete the questionnaires in English.
Patients were consecutively enrolled as they were identiﬁed
by the renal units. All study participants were prospectively
evaluated at baseline using the above assessment tools. The ques-
tionnaires were self-completed and administered by mail. Infor-
mation on demographic characteristics, race, and ethnicity was
obtained from self-report from patients who completed a ques-
tionnaire with ﬁxed response categories and the opportunity to
write in information. All study procedures were approved by the
Health Research Ethics Board of the University of Alberta.
Statistical Analyses
Patient characteristics were described as frequencies and percent-
ages or as a mean (SD). Descriptive statistics were obtained for
patient characteristics, comorbidity, depression, and HRQL
preference-based scores.Weights used to derive SF-6D preference-
based scoreswere those by Brazier et al. [5].Weights used to derive
preference-based scores from the HUI3 were those by Feeny et al.
[4].
The extent of agreement between the two instruments was
examined by comparing the mean preference-based scores using
paired t-tests. Visual inspection of the distributions of SF-6D
and HUI3 scores suggested that although the distribution for
the former was symmetric, the distribution for the latter was
skewed. A Levene’s test for equality of variances was used to
assess the equality of the two variances. Association between
the two measures was determined using Pearson product–
moment correlation coefﬁcients.
The intraclass correlation coefﬁcient (ICC) was used as a
measure of agreement. A strong correlation was deﬁned as
greater than 0.50, a moderate correlation as 0.35 to 0.50, a weak
correlation as 0.20 to 0.34, and a negligible correlation as 0 to
0.19 as suggested by Guyatt et al. [24]. The pattern of agreement
was examined graphically by plotting values obtained for the two
instruments.
The distribution of responses across the two descriptive
systems, speciﬁcally at the top and bottom of the scale for each
dimension, was examined to identify possible ceiling or ﬂoor
effects. The degree of association between the overlapping
dimensions of the SF-6D and HUI3 was measured using the
Spearman’s correlation coefﬁcient.
Two independent samples t-test were used to compare the
ability of the SF-6D and HUI3 to discriminate between patient
groups differing in burden of comorbidity using a CCI score of
8 as a cutoff for high comorbidity, disease severity deﬁned as
predialysis versus dialysis dependent, and depressive symptoms
using a BDI-II score of 14 as the cutoff. For descriptive pur-
poses, age and sex were also added to this analysis. SPSS 15.0
for windows was used to perform statistical analyses. A P < 0.05
was considered statistically signiﬁcant. Because hypotheses were
speciﬁed a priori, no adjustment was made for multiple testing.
Results
In total, 185 of the 230 patients approached for the master study
(80%) consented to participate. All 185 patients were evaluated
at baseline. Patient characteristics can be seen in Table 1. The
study participants were predominantly white (82.7%), had
an average age of 63.6 years, had signiﬁcant comorbidity, and
28% had BDI-II scores 14, suggestive of depression. Sixty-six
percent of patients were predialysis and 34% were on mainte-
nance hemodialysis. With the exception of race, the study
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participants were representative of the North American dialysis
population [25,26]. The mean preference-based score for the
SF-6D was 0.67 (0.13) compared to 0.58 (0.26) for the HUI3.
The difference was clinically and statistically signiﬁcant (0.09,
P < 0.01). Both preference-based scores are very low relative to
the general population, indicating substantial burden in HRQL.
The SF-6D population norm for community-dwelling subjects is
0.80 for men and 0.77 for women aged 65 to 74 years (0.79 and
0.76 for those 55–64) [12]. HUI3 population norms are 0.82 for
men and 0.79 for women aged 65 to 74 years (0.78 and 0.77 for
those 55–64) [12].
There is a strong association between SF-6D and HUI3
preference-based scores (Pearson product–moment correlation
coefﬁcient 0.55, 95% CI 0.43–0.65) and moderate agreement
with an ICC of 0.44 (Fig. 1). The SF-6D had a greater spread of
values between 0.90 and 1.0 whereas at values lower than 0.7,
the HUI3 exhibited a greater spread of values. The Spearman
rank correlations between SF-6D dimensions of bodily pain,
physical functioning, and mental health and the corresponding
HUI3 dimensions of pain, ambulation, and emotion were 0.62
(P < 0.01), 0.47 (P < 0.01), and 0.43 (P < 0.01), respectively.
The distributions of the levels for the attributes of the SF-6D
and HUI3 are shown in Tables 2 and 3, respectively. All levels for
each dimension of both instruments were used indicating con-
siderable heterogeneity in this population. The SF-6D had a
substantial proportion of respondents (23.8–38.9%) at the
ceiling for three of the six dimensions (role limitations, social,
and pain). The HUI3, however, had a substantial proportion of
its respondents at the ceiling (25.9–88.6%) for six of its eight
attributes. This was most noticeable for hearing and speech.
Nevertheless, these are the two HUI3 attributes not speciﬁcally
relevant to CKD. The percentages of respondents reporting full
function were 65.4% for dexterity, 45.4% for ambulation,
44.9% for cognition, and 36.2% for emotion. The SF-6D had
large ﬂoor effects for the dimension role limitations with 35.7%
of respondents reported the lowest functioning. The range of
proportions of patients at the ﬂoor for the remaining ﬁve SF-6D
dimensions was 4.9% to 7.0%. The HUI3 had essentially no
ﬂoor effects: no patients were at the lowest level of functioning
for four of the eight dimensions, and the remainder fell between
2.2% and 3.2%.
The distributions of the overall preference-based scores for
the SF-6D and HUI3 are presented in Figure 2. As expected, the
SF-6D has a normal distribution, and the HUI3 was skewed
toward lower values. The Levene’s test for equality of variances
indicated that the variances of the two distributions are not equal
(P < 0.001). The range of SF-6D scores was much smaller com-
pared to HUI3 scores. The HUI3 may have a greater ceiling effect
as 9% of participants had a preference score between 0.9 and 1.0
compared to 2% for the SF-6D. Floor effect appears larger with
the SF-6D as 16% of respondents had HUI3 scores below that of
the lowest SF-6D score.
The discriminative abilities of the SF-6D and HUI3 are com-
pared in Table 4. Both instruments were able to discriminate
between patients based on disease severity and BDI-II scores. The
study was underpowered to be able to conﬁrm the ability of
either tool to discriminate between patients based on comorbid-
ity. There were clinically important differences for scores for both
instruments between groups of patients based on age and sex,
although this was statistically signiﬁcant only for age for the
HUI3 which demonstrated lower scores and thus greater disabil-
ity for patients >55 years. For all categories, the differences in
preference scores between groups of patients were greater with
the HUI3 than the SF-6D, although due to the wider conﬁdence
intervals, this did not reach statistical signiﬁcance except for
depressive symptoms using the BDI-II score (P < 0.01).
Discussion
Determining the relative costs and beneﬁts of different interven-
tions has become a critical issue in optimizing care for patients
with CKD. Researchers have therefore begun to use multiat-
tribute HRQL measures to incorporate preferences for different
health states and to calculate QALYs and cost-effectiveness.
Table 1 Patients characteristics (n = 185)
Variables Mean (SD) or n (%)
Age in years 63.6 (12.2)
Race (% white) 82.7
Sex
Male 102 (55%)
Female 83 (45%)
Marital status
Single 32 (17.3%)
Married 104 (56.2%)
Widowed/divorced/separated 49 (26.5%)
Cause of chronic kidney disease
Diabetes mellitus 79 (42.7%)
Hypertension 29 (15.7%)
Glomerulonephritis 12 (6.5%)
Polycystic kidney disease 8 (4.3%)
Renovascular 4 (2.2%)
Other 25 (13.5%)
Unknown/missing 28 (15.2%)
Dialysis modality*
Predialysis 122 (66%)
Hemodialysis 62 (34%)
Months on dialysis—HD/PD patients 4.2 (6.0) (range 0.1–36)
Charlson Comorbidity Index* 9.5 (2.5) (range 4–16)
<8 23 (24%)
8 74 (76%)
Beck Depression Inventory II 10.4 (8.5) (range 0–40)
<14 129 (72%)
14 51 (28%)
SF-6D 0.67 (0.13) (range 0.37 to 1.00)†
HUI3 0.58 (0.26) (range -0.14 to 1.00)‡
*Dialysis status was missing for one person, the comorbidity information was missing for 88,
and the BDI-II was missing for ﬁve.
†Theoretical range: 0.296 to 1.0.
‡Theoretical range: -0.36 to 1.0.
HD, hemodialysis; HUI3, Health Utilities Index Mark 3; PD, peritoneal dialysis.
Figure 1 Scatterplot of HUI3 and SF-6D utility scores with linear regression
line and 45° (perfect agreement) line. HUI3, Health Utilities Index Mark 3.
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Unfortunately, no gold standard currently exists for preference-
based HRQL measurement. The SF-6D is a relatively new
instrument that permits SF-36 data to be transformed into
preference-based HRQL scores. Being able to use the SF-6D to
obtain HRQL scores may be advantageous in certain circum-
stances. Nevertheless, the HUI3 is a shorter, simpler tool that has
been widely used in numerous patient populations. There are
limited data comparing the application of these instruments. This
is one of the relatively few studies to compare the application of
these two widely used generic preference-based instruments in a
chronically ill population such as CKD.
Our ﬁndings indicate that there are clinically important
differences in the performance of the HUI3 and SF-6D in CKD.
There was a clinically important and statistically signiﬁcant
difference in the mean preference values between the two instru-
ments. Although the SF-6D and the HUI3 may measure similar
constructs and their scores are strongly correlated, the ICC
showed only moderate agreement between their preference-based
scores. Despite limited data in the literature comparing the HUI3
and SF-6D, these results are similar with those comparing their
application in hospitalized patients undergoing percutaneous
coronary intervention (Pearson product–moment correlation
coefﬁcient 0.62, ICC 0.40) [27] and in patients being treated for
high risk of sudden cardiac death (Pearson product–moment
correlation coefﬁcient 0.58, ICC 0.42) [28].
Differences in how health status are deﬁned and the range of
health states each measure intended to cover may account for
some of the differences in observed scores between the two
Table 2 Distribution of levels on SF-6D attributes (% of subjects)
Level
SF-6D
Physical functioning Role limitations Social functioning Bodily pain Mental health Vitality
1 7.6 38.9 30.3 23.8 8.6 6.5
2 21.1 13.0 24.9 4.3 30.3 38.9
3 35.1 2.7 21.1 29.2 27.6 27.0
4 22.2 35.7 10.8 18.4 26.5 19.5
5 5.9 N/A 4.9 14.6 7.0 7.0
6 7.0 N/A N/A 6.5 N/A N/A
Missing 1.1 9.7 8.1 3.2 0 1.1
N/A, not available.
Table 3 Distribution of levels on HUI3 attributes (% of subjects)
Level
HUI3
Vision Hearing Speech Ambulation Dexterity Cognition Emotion Pain
1 9.7 83.8 88.6 45.4 65.4 44.9 36.2 25.9
2 71.4 0.5 4.9 27.0 21.1 24.3 44.9 37.8
3 2.2 2.2 3.2 8.6 0.0 5.4 10.8 20.0
4 1.1 2.7 0.0 4.9 3.8 20.0 4.9 9.7
5 10.3 1.1 0.0 3.2 0.5 1.6 0.0 3.2
6 2.2 2.2 N/A 2.2 0.0 0.0 N/A N/A
Missing 3.2 7.6 3.2 8.6 9.2 3.8 3.2 3.2
HUI3, Health Utilities Index Mark 3; N/A, not available.
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instruments. Although the two instruments overlap in the dimen-
sions bodily pain—pain, physical functioning—ambulation, and
mental health—emotion, the content of the two measures are
clearly different in other aspects. TheHUI3 is based on a relatively
narrow “within-the-skin” approach to health that focuses on
impairments in sensation (vision, hearing, speech), cognition,
emotional and physical functioning. It was developed to be appli-
cable in both clinical and general population studies. The SF-36 is
based on the broader World Health Organization deﬁnition of
health and includes role (physical and emotional) limitations,
social functioning, and vitality and focuses on the health concerns
of a generally healthy population living in the community [1].
Thus, the two measures differ in the range of health conditions
each was intended to cover. Furthermore, the underlying deﬁni-
tions of health status differ with respect to the exclusion (HUI3)
and inclusion (SF-36) of social interaction as a component of
health status.
Differences in preference-based scores between the two
instruments may also reﬂect differences in the underlying func-
tion form of the scoring systems and differences in how the
scoring functions were estimated. The SF-6D health states were
directly valued by the standard gamble technique although the
HUI3 health states were directly valued by VAS with a subset of
states also being valued with the standard gamble. A power
function was then used to transform VAS to standard gamble
scores. The HUI3 scoring function is based on a multiplicative
multiattribute utility function that includes a term to capture the
effects of an interaction in preferences among the attributes. In
contrast, the SF-6D scoring function relies on a linear additive
model that assumes that there are no interactions in preferences
among the attributes. For SF-6D, 249 of a possible 18,000 SF-6D
health states were valued and the scores were used in regression
analyses to estimate linear additive models with the choice of
ﬁnal model being made on the basis of goodness-of-ﬁt and
parsimony.
The HUI3 appears less subject to ﬂoor effects than the SF-6D
and is better able to distinguish lower health states, particularly
states considered worse than dead which are not addressed by the
SF-6D. For example, seven patients reported health states for
which the scores were negative on the HUI3, indicating a health
state considered worse than dead by the general population. The
corresponding scores for these patients on the SF-6D ranged
from 0.38 to 0.59. The clinical implication is that these patients
have more disability than the ﬂoor of the SF-6D would indicate
and if they deteriorate, the SF-6D will not be able to capture this.
Conversely, the HUI3 is able to discriminate more precisely
among higher levels of impairment, a necessary requirement in a
patient population such as advanced CKD given their low HRQL
scores. This ﬂoor effect of the SF-6D compared to the HUI3 has
also been shown in hospitalized patients undergoing percutane-
ous coronary intervention [27], patients with intermittent clau-
dication [29], and patients being treated for high risk of sudden
cardiac death [28]. Several other studies have also presented
evidence on ﬂoor effect problems with SF-36 and/or SF-6D
[30–36].
The SF-6D appears less subject to ceiling effects than the
HUI3 and is better able to distinguish higher health states. For
patients with limited disability (particularly preference-based
scores >0.90), small improvements in health state may be missed
by the HUI3. Nevertheless, the clinical relevance of this in the
CKD population is likely limited.
A possible reason for the greater ﬂoor effect observed in the
SF-6D is that states considered worse than dead were not
explored. In contrast, substantial interview time was devoted to
quantifying how much worse than dead certain HUI3 health
states were. This is one of the reasons that HUI3 scores have
more “space” below dead, i.e., below zero. This is a critical issue
in CKD where states worse than dead are accepted and often
result in patients choosing to withdraw from life-sustaining
dialysis. A possible reason for the ceiling effect observed in the
HUI3 may be the exclusion of some important HRQL dimen-
sions relevant to this patient population such as vitality, role
limitations, and social functioning which are present in the
SF-6D. SF-36 also includes items on the ability to engage in
vigorous physical activity, whereas HUI3 refers to the ability to
get around without any difﬁculty. In healthy populations, the
omission of vigorous physical activity from HUI3 may contribute
to ceiling effects; this omission is unlikely to be clinically impor-
tant in CKD.
There was little disparity between the two instruments in
terms of their discriminant properties. Although mean differences
between groups were greater for the HUI3, these differences were
associated with greater standard deviation and hence did not
result in greater statistical signiﬁcance as compared to those
calculated for the SF-6D except for the HUI3’s ability to discrimi-
nate patients with greater BDI-II score.
Although these data were from nine units across Alberta, the
study subjects were primarily white and the results may not be
generalizable to the entire CKD population. Work that remains
outstanding is a comparison of the difference in preference-based
scores over time in response to treatment between these two
instruments. Subsequent data from this study will allow us to
determine this. This study only compared two preference-based
HRQL instruments but future research including other multiat-
tribute preference-based tools such as the EQ-5D may be helpful.
This study provides useful insight into the psychometric prop-
erties of the SF-6D and HUI3 with several implications for future
preference-based HRQL measurement and economic analyses in
CKD. Any comparison between HUI3 and SF-6D preference-
based scores and QALYs should be made with caution in CKD.
This is consistent with the limited evidence in the literature which
seems to indicate that measures deployed are not interchangeable
for use in cost-utility analyses [28,37]. The HUI3 descriptive
Table 4 HUI3 and SF-6D score comparisons by demographics, Charl-
son Comorbidity Index (CCI), dialysis status, and Beck Depression Inven-
tory II (BDI-II)
Variables n
Mean (SD)
SF-6D HUI3
Age in years
<55 34 0.69 (0.14) 0.68 (0.22)
55 134 0.66 (0.13) 0.55 (0.27)
Delta 0.03 0.13**
Sex
Male 92 0.68 (0.13) 0.60 (0.25)
Female 76 0.65 (0.13) 0.56 (0.28)
Delta 0.03 0.05
CCI
<8 23 0.72 (0.13) 0.63 (0.22)
8 74 0.66 (0.12) 0.55 (0.23)
Delta 0.06† 0.08
Dialysis status
Predialysis 116 0.69 (0.13) 0.62 (0.22)
Dialysis 62 0.62 (0.13) 0.51 (0.31)
Delta 0.07** 0.09*
BDI-II
<14 127 0.70 (0.13) 0.65 (0.22)
14 49 0.57 (0.08) 0.38 (0.28)
Delta 0.13*** 0.27***
*P < 0.05, **P < 0.01, ***P < 0.001, †P = 0.055.
HUI3, Health Utilities Index Mark 3.
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system was created with greater simplicity compared to the
SF-6D. Nevertheless, despite being briefer, the HUI3 was better
able to capture more severe burden of illness with fewer ﬂoor
effects. Nevertheless, the SF-6D was better at discriminating
among subjects at the top range of the scale. This suggests that the
HUI3 would be more suitable for measuring the health of popu-
lations with more morbidity and disability such as patients with
CKD. It remains to be determined whether these differences
will remain when one compares within-instrument differences
in preference-based scores over time. Researchers must select an
instrument sensitive to the health states under investigation.
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